Evidence map›Paper›PMID 33395782›Full record

ReviewDiabetes & metabolic syndrome

New onset diabetes, type 1 diabetes and COVID-19.

Sirisha Kusuma Boddu, Geeta Aurangabadkar, Mohammad Shafi Kuchay

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 9 pooled it
3.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 9 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic Review.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Pooled it
  8. Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes.Translational research : the journal of laboratory and clinical medicine · 2022
    Pooled it
  9. Pooled it
  10. Article
  11. Ketoacidosis in new-onset type 1 diabetes: return to pre-COVID-19 pandemic reality?Pediatric endocrinology, diabetes, and metabolism · 2026
    Observational
  12. Review
  13. Review
  14. Article
  15. Role of nutrition in diabetes mellitus and infections.World journal of clinical cases · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Sirisha Kusuma BodduDepartment of Pediatric Endocrinology, Rainbow Children's Hospital, Hyderabad, India.
Geeta AurangabadkarDepartment of Endocrinology, CARE Multispecialty Hospital, Hyderabad, India. Electronic address: vrgeeta@yahoo.com.
Mohammad Shafi KuchayDivision of Endocrinology and Diabetes, Medanta the Medicity Hospital, Haryana, India.
CARE Hospitals · INMedanta The Medicity · INRainbow Children's Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsNew data has emerged regarding higher risk of coronavirus disease 2019 (COVID-19), and its severity and complications in patients with type 2 diabetes mellitus (T2DM). However, there is a dearth of evidence regarding type 1 diabetes mellitus (T1DM). This article explores the possibility of COVID 19 induced diabetes and highlights a potential bidirectional link between COVID 19 and T1DM.

methodsA literature search was performed with Medline (PubMed), Scopus, and Google Scholar electronic databases till October 2020, using relevant keywords (COVID-19 induced diabetes; COVID-19 and type 1 diabetes; COVID-19 induced DKA; new-onset diabetes after SARS-CoV-2 infection) to extract relevant studies describing relationship between COVID-19 and T1DM.

resultsPast lessons and new data teach us that severe acute respiratory syndrome coronaviruses (SARS-CoV and SARS-CoV-2) can enter islet cells via angiotensin converting enzyme-2 (ACE-2) receptors and cause reversible β-cell damage and transient hyperglycemia. There have been postulations regarding the potential new-onset T1DM triggered by COVID-19. This article reviews the available evidence regarding the impact and interlink between COVID-19 and Τ1DM. We also explore the mechanisms behind the viral etiology of Τ1DM.

conclusionsSARS-CoV-2 can trigger severe diabetic ketoacidosis at presentation in individuals with new-onset diabetes. However, at present, there is no hard evidence that SARS-CoV-2 induces T1DM on it's own accord. Long term follow-up of children and adults presenting with new-onset diabetes during this pandemic is required to fully understand the type of diabetes induced by COVID-19.

Indexed as

Angiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsCOVID-19COVID-19 Drug TreatmentDiabetes Mellitus, Type 1HumansACE2 protein, humanAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsACE2 receptorsHyperglycemiaNew-onset diabetesSARS-CoV-2Type 1 diabetesβ-cell damage

Identifiers

PMID33395782
PMCPMC7669477
OpenAlexW3100694757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.